Bacterial Vaginoses Clinical Trial
Official title:
Treatment of Bacterial Vaginosis Prior to Active Labor and Infectious Morbidity: A Randomized Controlled Trial
Bacterial vaginosis (BV) is the most common cause of vaginal discharge among repro-ductive aged women. It is been linked to adverse maternal and neonatal outcomes. Our objective is to evaluate if the use of a single dose of metronidazole in women with BV at time of delivery reduces infectious morbidities
The investigators are proposing a double-blinded, placebo controlled, randomized trial of 525 pregnant women undergoing induction or admitted in early labor and who are diagnosed with bacterial vaginosis. On admission to labor and delivery, patient will be counseled about the study. Patients who agree to be enrolled, will sign informed consent. Following enrollment patients will be screened for Bacterial vaginosis by doing a speculum exam and testing for Amsel's criteria. BV +ve patients will be randomized to receive either metronidazole 2 grams PO once or identically appearing placebo. The PI, study coordinator, or a collaborator will be responsible for the informed consent. This will be a double-blinded randomized clinical trial. Neither the patient nor provider will be aware of treatment assignment. As with any other in-stance in which antibiotics are administered, there is a chance of an allergic or other adverse reaction. The patient will receive standard inpatient monitoring during the labor course and in the postpartum period, and so any immediate adverse reaction would be promptly detected. Patient will be assessed intrapartum for development of chorioamninoitis. Postpartum patient will be assessed for infective complications up to 4 weeks. Neonates will be assessed for morbidities by chart review for 90 days. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04329338 -
Effects of Lactobacillus Pentosus KCA1 on the Gut and Vaginal Microbiome of Women With Bacterial Vaginosis
|
N/A | |
Completed |
NCT03837015 -
Estrogen, Probiotics and Vaginal Health to Prevent HIV Infection in ACB Women
|
Phase 1 | |
Completed |
NCT03937869 -
Evaluate the Safety of a Single Oral Dose of Solosecâ„¢ (Secnidazole) 2g for the Treatment of Adolescent Girls With BV
|
Phase 4 | |
Completed |
NCT03878511 -
Therapeutic Lactose to Support Vaginal Microbiota
|
N/A | |
Not yet recruiting |
NCT04846361 -
Vaginal Hygiene Wash as Adjunct Treatment in Bacterial Vaginosis
|
N/A | |
Completed |
NCT04057482 -
Treatment of BV With Donaxyl and a Molecular Test of Cure
|
||
Completed |
NCT04393857 -
The Temporo-spatial Dynamics of Genital Tract Microbiota - an Observational Study in Oocyte Donors
|
||
Completed |
NCT04414527 -
Effects of Video-based Health Education on Maternal and Child Health in Ethiopia
|
N/A | |
Recruiting |
NCT04807842 -
Multi-Gyn ActiGel Plus for Treatment of Bacterial Vaginosis
|
N/A | |
Recruiting |
NCT05166746 -
The Effect of Clindamycin and a Live Biotherapeutic on the Reproductive Outcomes of IVF Patients With Abnormal Vaginal Microbiota
|
Phase 2 | |
Completed |
NCT04189744 -
The ASPIRE Trial - Aiming for Safe Pregnancies by Reducing Malaria and Infections of the Reproductive Tract
|
Phase 3 | |
Recruiting |
NCT04517487 -
Vaginal Microbiome Transplantation for Recurrent Bacterial Vaginosis
|
N/A | |
Recruiting |
NCT04885556 -
Evaluation of a Novel Female Hygiene Device for Postcoital Discomfort
|
N/A | |
Terminated |
NCT04578015 -
A Randomized Controlled Trial of Treatment of Bacterial Vaginosis
|
Phase 4 | |
Completed |
NCT06104098 -
A User Study With Vernivia® for Bacterial Vaginosis.
|
N/A |